Altimmune (ALT) Other Non-Current Assets (2010 - 2026)
Altimmune (ALT) reported Other Non-Current Assets of $746000.0 for Q1 2026, down 53.87% year-over-year from $1.6 million in Q1 2025, and down 47.65% on a QoQ basis from $1.4 million in Q4 2025.
Altimmune (ALT) has 17 years of Other Non-Current Assets data on file, last reported at $746000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 53.87% year-over-year to $746000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $746000.0 (down 53.87% YoY) and the FY2025 annual result came in at $1.4 million, down 13.06% from the prior year.
- Other Non-Current Assets eased to $746000.0 in Q1 2026 per ALT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.7 million in Q2 2024 and bottomed at $299000.0 in Q1 2024.
- The 5-year median for Other Non-Current Assets is $747000.0 (2022), against an average of $987823.5.
- The widest annual swing landed in 2022, when Other Non-Current Assets soared 603.38%; it then sank 53.87% in 2026.
- Tracing ALT's Other Non-Current Assets over 5 years: stood at $615000.0 in 2022, then tumbled by 40.98% to $363000.0 in 2023, then jumped by 351.52% to $1.6 million in 2024, then fell by 13.06% to $1.4 million in 2025, then plunged by 47.65% to $746000.0 in 2026.
- Per Business Quant, the three latest ALT Other Non-Current Assets figures stand at $746000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 746,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 746,000.00 |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 299,000.00 |
| Dec 31, 2023 | 363,000.00 |
| Sep 30, 2023 | 425,000.00 |
| Jun 30, 2023 | 483,000.00 |
| Mar 31, 2023 | 546,000.00 |
| Dec 31, 2022 | 615,000.00 |
| Sep 30, 2022 | 682,000.00 |
| Jun 30, 2022 | 747,000.00 |
| Mar 31, 2022 | 811,000.00 |
| Dec 31, 2021 | 872,000.00 |
| Sep 30, 2021 | 931,904.00 |
| Jun 30, 2021 | 928,839.00 |
| Mar 31, 2021 | 115,300.00 |
| Dec 31, 2020 | 977,238.00 |
| Sep 30, 2020 | 87,195.00 |
| Jun 30, 2020 | 100,980.00 |
| Mar 31, 2020 | 114,764.00 |
| Dec 31, 2019 | 128,547.00 |
| Sep 30, 2019 | 142,331.00 |
| Jun 30, 2019 | 156,115.00 |
| Mar 31, 2019 | 169,898.00 |
| Dec 31, 2018 | 183,682.00 |
| Sep 30, 2018 | 1.15 Mn |
| Jun 30, 2018 | 411,250.00 |
| Mar 31, 2018 | 225,133.00 |
| Dec 31, 2017 | 238,917.00 |
| Sep 30, 2017 | 22,248.00 |
| Jun 30, 2017 | 22,247.00 |
| Dec 31, 2016 | 22,248.00 |
| Mar 31, 2016 | 53,384.00 |
| Dec 31, 2015 | 53,384.00 |
| Sep 30, 2015 | 53,384.00 |
| Jun 30, 2015 | 53,384.00 |
| Mar 31, 2015 | 53,384.00 |
| Dec 31, 2014 | 53,384.00 |
| Jun 30, 2014 | 55,032.00 |
| Mar 31, 2014 | 59,132.00 |
| Dec 31, 2013 | 65,660.00 |
| Sep 30, 2013 | 74,594.00 |
| Jun 30, 2013 | 85,907.00 |
| Mar 31, 2013 | 99,578.00 |
| Dec 31, 2012 | 113,130.00 |
| Sep 30, 2012 | 130,709.00 |
| Jun 30, 2012 | 150,479.00 |
| Mar 31, 2012 | 174,525.00 |
| Dec 31, 2011 | 100,000.00 |
| Sep 30, 2011 | 53,384.00 |
| Jun 30, 2011 | 53,384.00 |
| Dec 31, 2010 | 100,000.00 |